297 related articles for article (PubMed ID: 31118614)
1. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.
Ullah A; Wang K; Wu P; Oupicky D; Sun M
Int J Nanomedicine; 2019; 14():2927-2944. PubMed ID: 31118614
[No Abstract] [Full Text] [Related]
2. A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis.
Ullah A; Chen G; Yibang Z; Hussain A; Shafiq M; Raza F; Liu D; Wang K; Cao J; Qi X
Biomater Sci; 2022 May; 10(10):2650-2664. PubMed ID: 35420075
[TBL] [Abstract][Full Text] [Related]
3. Dual-function nanostructured lipid carriers to deliver IR780 for breast cancer treatment: Anti-metastatic and photothermal anti-tumor therapy.
Li H; Wang K; Yang X; Zhou Y; Ping Q; Oupicky D; Sun M
Acta Biomater; 2017 Apr; 53():399-413. PubMed ID: 28159715
[TBL] [Abstract][Full Text] [Related]
4. CXCR4-Receptor-Targeted Liposomes for the Treatment of Peritoneal Fibrosis.
Asifullah K; Zhou Z; He W; Gao K; Khan MW; Faisal R; Muhammad H; Sun M
Mol Pharm; 2019 Jun; 16(6):2728-2741. PubMed ID: 31070930
[TBL] [Abstract][Full Text] [Related]
5. Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl
Ullah A; Chen G; Hussain A; Khan H; Abbas A; Zhou Z; Shafiq M; Ahmad S; Ali U; Usman M; Raza F; Ahmed A; Qiu Z; Zheng M; Liu D
Int J Nanomedicine; 2021; 16():4451-4470. PubMed ID: 34234436
[TBL] [Abstract][Full Text] [Related]
6. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Liu CH; Chan KM; Chiang T; Liu JY; Chern GG; Hsu FF; Wu YH; Liu YC; Chen Y
Mol Pharm; 2016 Jul; 13(7):2253-62. PubMed ID: 27224003
[TBL] [Abstract][Full Text] [Related]
7. Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis.
Bansal R; Prakash J; de Ruijter M; Beljaars L; Poelstra K
Mol Pharm; 2011 Oct; 8(5):1899-909. PubMed ID: 21800888
[TBL] [Abstract][Full Text] [Related]
8. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Sung YC; Liu YC; Chao PH; Chang CC; Jin PR; Lin TT; Lin JA; Cheng HT; Wang J; Lai CP; Chen LH; Wu AY; Ho TL; Chiang T; Gao DY; Duda DG; Chen Y
Theranostics; 2018; 8(4):894-905. PubMed ID: 29463989
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of p38 MAPK mediates protective effects of hydrogen sulfide on hepatic fibrosis.
Fan HN; Wang HJ; Ren L; Ren B; Dan CR; Li YF; Hou LZ; Deng Y
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):644-52. PubMed ID: 23543448
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid modified extracellular vesicles targeting hepatic stellate cells to attenuate hepatic fibrosis.
Yu F; Liu Z; Feng J; Man Y; Zhang H; Shi J; Pang X; Yu Y; Bi Y
Eur J Pharm Sci; 2024 Jul; 198():106783. PubMed ID: 38703918
[TBL] [Abstract][Full Text] [Related]
11. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
12. miR-140-3p Knockdown Suppresses Cell Proliferation and Fibrogenesis in Hepatic Stellate Cells via PTEN-Mediated AKT/mTOR Signaling.
Wu SM; Li TH; Yun H; Ai HW; Zhang KH
Yonsei Med J; 2019 Jun; 60(6):561-569. PubMed ID: 31124340
[TBL] [Abstract][Full Text] [Related]
13. Ankaflavin and Monascin Induce Apoptosis in Activated Hepatic Stellate Cells through Suppression of the Akt/NF-κB/p38 Signaling Pathway.
Cheng CF; Pan TM
J Agric Food Chem; 2016 Dec; 64(49):9326-9334. PubMed ID: 27960292
[TBL] [Abstract][Full Text] [Related]
14. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
15. Chemically modified liposomes carrying TRAIL target activated hepatic stellate cells and ameliorate hepatic fibrosis in vitro and in vivo.
Li Q; Ding Y; Guo X; Luo S; Zhuang H; Zhou J; Xu N; Yan Z
J Cell Mol Med; 2019 Mar; 23(3):1951-1962. PubMed ID: 30592139
[TBL] [Abstract][Full Text] [Related]
16. Cortex Dictamni extract induces apoptosis of activated hepatic stellate cells via STAT1 and attenuates liver fibrosis in mice.
Wu XX; Wu LM; Fan JJ; Qin Y; Chen G; Wu XF; Shen Y; Sun Y; Xu Q
J Ethnopharmacol; 2011 Apr; 135(1):173-8. PubMed ID: 21396998
[TBL] [Abstract][Full Text] [Related]
17. Albumin self-modified liposomes for hepatic fibrosis therapy via SPARC-dependent pathways.
Wang J; Ding Y; Zhou W
Int J Pharm; 2020 Jan; 574():118940. PubMed ID: 31830578
[TBL] [Abstract][Full Text] [Related]
18. Curcumin protects against hepatic stellate cells activation and migration by inhibiting the CXCL12/CXCR4 biological axis in liver fibrosis：A study in vitro and in vivo.
Qin L; Qin J; Zhen X; Yang Q; Huang L
Biomed Pharmacother; 2018 May; 101():599-607. PubMed ID: 29518606
[TBL] [Abstract][Full Text] [Related]
19. Indole-3-carbinol enhances the resolution of rat liver fibrosis and stimulates hepatic stellate cell apoptosis by blocking the inhibitor of κB kinase α/inhibitor of κB-α/nuclear factor-κB pathway.
Ping J; Gao AM; Qin HQ; Wei XN; Bai J; Liu L; Li XH; Li RW; Ao Y; Wang H
J Pharmacol Exp Ther; 2011 Nov; 339(2):694-703. PubMed ID: 21862660
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.
Zhao XY; Zeng X; Li XM; Wang TL; Wang BE
Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):963-8. PubMed ID: 19413596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
